List of Figures
Figure 1: Total Prevalent/Incident Cases of the Mucopolysaccharidosis I in 7MM
Figure 2: Total Prevalent/Incident Cases of the Mucopolysaccharidosis I in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Figure 4: Sub-Type Specific cases of the Mucopolysaccharidosis I in United States (2017-2028)
Figure 5: Sex- Specific Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Figure 6: Diagnosed Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Figure 7: Treatable Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Figure 8: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Figure 9: Sub-Type Specific cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Figure 10: Sex- Specific Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Figure 11: Diagnosed Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Figure 12: Treatable Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Figure 13: Prevalent/Incident Cases of the Mucopolysaccharidosis I in France (2017-2028)
Figure 14: Sub-Type Specific cases of the Mucopolysaccharidosis I in France (2017-2028)
Figure 15: Sex- Specific Cases of the Mucopolysaccharidosis I in France (2017-2028)
Figure 16: Diagnosed Cases of the Mucopolysaccharidosis I in France (2017-2028)
Figure 17: Treatable Cases of the Mucopolysaccharidosis I in France (2017-2028)
Figure 18: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Figure 19: Sub-Type Specific cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Figure 20: Sex- Specific Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Figure 21: Diagnosed Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Figure 22: Treatable Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Figure 23: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Figure 24: Sub-Type Specific cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Figure 25: Sex- Specific Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Figure 26: Diagnosed Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Figure 27: Treatable Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Figure 28: Prevalent/Incident Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Figure 29: Sub-Type Specific cases of the Mucopolysaccharidosis I in UK (2017-2028)
Figure 30: Sex- Specific Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Figure 31: Diagnosed Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Figure 32: Treatable Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Figure 33: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Figure 34: Sub-Type Specific cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Figure 35: Sex- Specific Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Figure 36: Diagnosed Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Figure 37: Treatable Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 42:7MM- Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 43:7MM- Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 44: United States-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 45: United States-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 46: United States-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 47: Germany-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 48: Germany-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 49: Germany-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 50: France-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 51: France-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 52: France-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 53: Italy-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 54: Italy-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 55: Italy-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 56: Spain-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 57: Spain-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 58: Spain-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 59:UK-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 60:UK-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 61:UK-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 62: Japan-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Figure 63: Japan-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Figure 64: Japan-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)


List of Tables
Table 1: Total Prevalent/Incident Cases of the Mucopolysaccharidosis I in 7MM
Table 2: Total Prevalent/Incident Cases of the Mucopolysaccharidosis I in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Table 4: Sub-Type Specific cases of the Mucopolysaccharidosis I in United States (2017-2028)
Table 5: Sex- Specific Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Table 6: Diagnosed Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Table 7: Treatable Cases of the Mucopolysaccharidosis I in United States (2017-2028)
Table 8: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Table 9: Sub-Type Specific cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Table 10: Sex- Specific Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Table 11: Diagnosed Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Table 12: Treatable Cases of the Mucopolysaccharidosis I in Germany (2017-2028)
Table 13: Prevalent/Incident Cases of the Mucopolysaccharidosis I in France (2017-2028)
Table 14: Sub-Type Specific cases of the Mucopolysaccharidosis I in France (2017-2028)
Table 15: Sex- Specific Cases of the Mucopolysaccharidosis I in France (2017-2028)
Table 16: Diagnosed Cases of the Mucopolysaccharidosis I in France (2017-2028)
Table 17: Treatable Cases of the Mucopolysaccharidosis I in France (2017-2028)
Table 18: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Table 19: Sub-Type Specific cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Table 20: Sex- Specific Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Table 21: Diagnosed Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Table 22: Treatable Cases of the Mucopolysaccharidosis I in Italy (2017-2028)
Table 23: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Table 24: Sub-Type Specific cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Table 25: Sex- Specific Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Table 26: Diagnosed Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Table 27: Treatable Cases of the Mucopolysaccharidosis I in Spain (2017-2028)
Table 28: Prevalent/Incident Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Table 29: Sub-Type Specific cases of the Mucopolysaccharidosis I in UK (2017-2028)
Table 30: Sex- Specific Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Table 31: Diagnosed Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Table 32: Treatable Cases of the Mucopolysaccharidosis I in UK (2017-2028)
Table 33: Prevalent/Incident Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Table 34: Sub-Type Specific cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Table 35: Sex- Specific Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Table 36: Diagnosed Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Table 37: Treatable Cases of the Mucopolysaccharidosis I in Japan (2017-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 42:7MM- Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 43:7MM- Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 44: United States-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 45: United States-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 46: United States-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 47: Germany-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 48: Germany-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 49: Germany-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 50: France-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 51: France-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 52: France-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 53: Italy-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 54: Italy-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 55: Italy-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 56: Spain-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 57: Spain-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 58: Spain-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 59:UK-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 60:UK-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 61:UK-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 62: Japan-Market Size of Mucopolysaccharidosis I in USD MM (2017-2028)
Table 63: Japan-Market Share Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)
Table 64: Japan-Market Sales of Mucopolysaccharidosis I by Therapies in USD MM (2017-2028)